Similarly, in breast cancer, elevated levels of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1) are associated with tumor aggressiveness and poor prognosis [19]. This evidence concerns the gene PLAU and breast cancer.